ROCKWOOL A/S
ROCKWOOL A/S – transactions in connection with share buy-back programme
ROCKWOOL A/S – transactions in connection with share buy-back programme
Company announcement
for ROCKWOOL A/S
Release no. 05 – 2025
to Nasdaq Copenhagen
22 January 2025
ROCKWOOL A/S – transactions in connection with share buy-back programme
As mentioned in announcement no. 02/2024, ROCKWOOL A/S has initiated a share buy-back programme which will run from 8 February 2024 until 7 February 2025. During this period, the Company will buy own shares for up to a maximum of 160 MEUR.
The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation.
The following transactions have been executed during the period 15 – 21 January 2025:
Date | Number of B shares | Average purchase price B shares (DKK) | Aggregate amount, B shares (DKK) |
[Accumulated, last announcement] | 448,200 | 1,162,842,642 | |
15 January 2025 | 2,500 | 2,481.23 | 6,203,075 |
16 January 2025 | 2,500 | 2,485.29 | 6,213,225 |
17 January 2025 | 2,500 | 2,537.92 | 6,344,800 |
20 January 2025 | 2,000 | 2,565.13 | 5,130,260 |
21 January 2025 | 2,430 | 2,571.69 | 6,249,207 |
Accumulated under the programme (B shares) | 460,130 | 1,192,983,209 |
With the transactions stated above, ROCKWOOL A/S owns 514,013 B shares corresponding to 2.38 percent of the Company’s total share capital.
An overview showing the transaction data for the period 15 – 21 January 2025 is enclosed.
This concludes the share buy-back programme.
Further information:
Kim Junge Andersen
Senior Vice President, CFO
ROCKWOOL A/S
+45 46 55 80 15
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom